Join to view full profile
3400 Spruce St2 Rhoads PavilionPhiladelphia, PA 19104
Phone+1 215-662-2737
Fax+1 215-349-8339
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Steven Fakharzadeh, MD is a board certified dermatologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
University of Pennsylvania Health SystemResidency, Dermatology, 1993 - 1996
Washington University/B-JH/SLCH ConsortiumInternship, Internal Medicine, 1991 - 1992
Perelman School of Medicine at the University of PennsylvaniaClass of 1991
Certifications & Licensure
PA State Medical License 1994 - 2026- PA State Medical License 1995 - 2026
American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
Publications & Presentations
PubMed
- 2 citationsResidual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2.Andrew Blauvelt, Kenneth B Gordon, Richard G Langley, Patrick J Branigan, Yanqing Chen
The Journal of Investigative Dermatology. 2024-12-01 - 4 citationsDifferential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy.Andrew Blauvelt, Yanqing Chen, Patrick J Branigan, Xuejun Liu, Samuel DePrimo
JID Innovations. 2024-09-01 - 31 citationsGuselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized study.Alexa B Kimball, Maurizio Podda, Afsaneh Alavi, Megan Miller, Yaung-Kaung Shen
Journal of the European Academy of Dermatology and Venereology. 2023-10-01
